PCI Biotech Holding ASA PCIB
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- NOK 1.54
- Day Range
- NOK 1.50–1.60
- 52-Week Range
- NOK 1.20–3.40
- Bid/Ask
- NOK 1.50 / NOK 1.90
- Market Cap
- NOK 59.65 Mil
- Volume/Avg
- 14,486 / 76,690
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
PCI Biotech Holding ASA is a biopharmaceutical company. It focuses on developing and commercializing therapies for the treatment of cancer through its photochemical internalization (PCI) technology platform. The PCI technology works by inducing light-triggered endosomal release. PCI is applied to three distinct anticancer paradigms; fimaCHEM which is an enhancement of chemotherapeutics for localized treatment of cancer, fimaVACC which is T-cell induction technology for therapeutic vaccination, and fimaNAc which is nucleic acid therapeutics delivery. Its therapeutic product candidate is the photosensitizer fimaporfin (Amphinex) which can unlock the intracellular capsules where active compounds are trapped.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 7
- Website
- https://www.pcibiotech.com
Valuation
|
Metric
|
PCIB
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 1.53 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
PCIB
|
|---|---|
Quick Ratio | 8.72 |
Current Ratio | 8.80 |
Interest Coverage | −139.89 |
Quick Ratio
PCIB
Profitability
|
Metric
|
PCIB
|
|---|---|
Return on Assets (Normalized) | −33.74% |
Return on Equity (Normalized) | −37.56% |
Return on Invested Capital (Normalized) | −41.02% |
Return on Assets
PCIB
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Qjydmbvtz | Qsflp | $545.9 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Qryjhynn | Mhjdv | $105.4 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Vthwsgpy | Kqkfnh | $103.7 Bil | |
MRNA
| Moderna Inc | Tdrnbzgd | Wmrsw | $47.9 Bil | |
ARGX
| argenx SE ADR | Nmdkjxnt | Dpl | $22.9 Bil | |
BNTX
| BioNTech SE ADR | Mtwgnxw | Tnjwx | $22.3 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Qqsmnqgp | Rsjxpz | $19.3 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Xlvjnshrx | Lmwdvf | $15.7 Bil | |
RPRX
| Royalty Pharma PLC Class A | Ynlwghrb | Mxyrdn | $12.8 Bil | |
INCY
| Incyte Corp | Bfvgtnnj | Wzhcww | $12.1 Bil |